|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Adjuvant chemotherapy for resected colorectal cancermetastases:literature review and meta-analysis显示文摘Surgical resection is the only option of cure for patients with metastatic colorectal cancer(CRC). However, the risk of recurrence within 18 mo after metastasectomy is around 75% and the liver is the most frequent site of relapse. The current international guidelines recommend an adjuvant therapy after surgical resection of CRC metastases despite the lower level of evidence(based on the quality of studies in this setting). However, there is still no standard treatment and the effective role of an adjuvant therapy remains controversial. The aim of this review is to report the state-of-art of systemic chemotherapy and regional chemotherapy with hepatic arterial infusion in the management of patients after resection of metastases from CRC, with a literature review and meta-analysis of the relevant randomized controlled trials. | Giovanni Brandi Stefania De Lorenzo Margherita Nannini Stefania Curti Marta Ottone Filippo Gustavo Dall’Olio Maria Aurelia Barbera Maria Abbondanza Pantaleo Guido Biasco | 2016 | World Journal of Gastroenterology2016，22，2： | 13 |
| 2 | Ten years of hip fractures in Italy: For the first time a decreasing trend in elderly women显示文摘AIM:To evaluate the hospitalization rate of femoralneck fractures in the elderly Italian population over ten years.METHODS:We analyzed national hospitalizations records collected at central level by the Ministry of Health from 2000 to 2009.Age-and sex-specific rates of fractures occurred at femoral neck in people≥65 years old.We performed a sub-analysis over a three-year period(2007-2009),presenting data per five-year age groups,in order to evaluate the incidence of the hip fracture in the oldest population.RESULTS:We estimated a total of 839008 hospitalizations due to femoral neck fractures between 2000 and2009 in people≥65,with an overall increase of 29.8%over 10 years.The incidence per 10000 inhabitants remarkably increased in people≥75,passing from158.5 to 166.8(+5.2%)and from 72.6 to 77.5(+6.8%)over the ten-year period in women and men,respectively.The oldest age group(people>85 years old)accounted for more than 42%of total hospital admissions in 2009(n=39000),despite representing only 2.5%of the Italian population.Particularly,women aged>85accounted for 30.8%of total fractures,although they represented just 1.8%of the general population.The results of this analysis indicate that the incidence of hip fractures progressively increased from 2000 to 2009,but a reduction can be observed for the first time in women≤75(-7.9%between 2004 and 2009).CONCLUSION:Incidence of hip fractures in Italy are continuously increasing,although women aged 65-74years old started showing a decreasing trend. | Prisco Piscitelli Maurizio Feola Cecilia Rao Monica Celi Elena Gasbarra Cosimo Neglia Giuseppe Quarta Federico Maria Liuni Simone Parri Giovanni Iolascon Maria Luisa Brandi Alessandro Distante Umberto Tarantino | 2014 | World Journal of Orthopedics2014，5，3： | 2 |
| 3 | Sustained complete response of advanced hepatocellular carcinoma with metronomic capecitabine: a report of three cases显示文摘Background:Hepatocellular carcinoma(HCC)is one of the most frequent causes of cancer-related death.Sorafenib,a multitarget angiogenesis inhibitor,is an approved frontline treatment for advanced HCC in Western countries,although a complete response(CR)to treatment is infrequently reported.Capecitabine,an oral fluoropyrimidine,has been shown to be effect in both treatment-naïve patients and those previously treated with sorafenib.To date,how-ever,only one case of sustained CR to metronomic capecitabine has been reported.Case presentation:We describe three cases of advanced HCC treated with metronomic capecitabine where a CR was obtained.In the first case,capecitabine was administered as first line therapy;in the second case,capecitabine was used after intolerance to sorafenib;while in the third case,capecitabine was administered after sorafenib failure.Conclusion:Capecitabine is a potentially important treatment option for patients with advanced HCC and may even represent a cure in certain cases. | Giovanni Brandi Michela Venturi Stefania De Lorenzo Francesca Garuti Giorgio Frega Andrea Palloni Ingrid Garajovà Francesca Abbati Gioconda Saccoccio Rita Golfieri Maria Abbondanza Pantaleo Maria Aurelia Barbera | 2018 | Cancer Communications2018，38，1： | 2 |
| 4 | High Prevalence of Celiac Disease in Italian General Population显示文摘 | Umberto Volta Stefano Bellentani Francesco Bianco Bianchi Giovanni Brandi Lucia De Franceschi Lucia Miglioli Alessandro Granito Fiorella Balli Claudio Tiribelli | 2001 | Digestive Diseases and Sciences2001，，7： | 1 |
| 5 | Changes in the surgical approach to hilar cholangiocarcinoma during an 18-year period in a Western single center显示文摘 | Giorgio Ercolani Matteo Zanello Gian Luca Grazi Matteo Cescon Matteo Ravaioli Massimo Gaudio Gaetano Vetrone Alessandro Cucchetti Giovanni Brandi Giovanni Ramacciato Antonio Daniele Pinna | 2010 | Journal of Hepato-Biliary-Pancreatic Sciences2010，，3： | 1 |
| 6 | Is post-transplant chemotherapy feasible in liver transplantation for colorectal cancer liver metastases?显示文摘Dear Editor:In the last two decades,the indications of liver transplantation(LT)for primary and secondary hepatobiliary malignancies have been increasingly expanded.Although this attractive option still represents the“last court of appeal”in cancer patients,the role of LT is well established in hepatocellular carcinoma(HCC),where transplantation has also demonstrated a benefit for selected patients affected by peri-hilar cholangiocarcinoma,intrahepatic cholangiocarcinoma,and neuroendocrine tumors[1].Recently,the interest in LT in liver-limited stage IV colorectal cancer(CRC)has increased due to recent advances in transplantation techniques that have led to a re-evaluation of this approach. | Giovanni Brandi Angela Dalia Ricci Alessandro Rizzo Chiara Zanfi Simona Tavolari Andrea Palloni Stefania De Lorenzo Matteo Ravaioli Matteo Cescon | 2020 | Cancer Communications2020，40，9： | 1 |
| 7 | Asbestos: a hidden player behind the cholangiocarcinoma increase? Findings from a case–control analysis显示文摘 | Giovanni Brandi Stefania Girolamo Andrea Farioli Francesco Rosa Stefania Curti Antonio Daniele Pinna Giorgio Ercolani Francesco Saverio Violante Guido Biasco Stefano Mattioli | 2013 | Cancer Causes & Control2013，，5： | 1 |
| 8 | Intrahepatic Cholangiocarcinoma: Primary Liver Resection and Aggressive Multimodal Treatment of Recurrence Significantly Prolong Survival显示文摘 | Giorgio Ercolani Gaetano Vetrone Gian Luca Grazi Osamu Aramaki Matteo Cescon Matteo Ravaioli Carla Serra Giovanni Brandi Antonio Daniele Pinna | 2010 | Annals of Surgery2010，，1： | 1 |
| 9 | Cold single-strand conformation polymorphism analysis: Optimizationfor detection of APC gene mutations in patients with familial adenomatous polyposis显示文摘 | Pierluigi Strippoli Silvia Sarchielli Renato Santucci Gian Bagnara Giovanni Brandi Guido Biasco | 2001 | International Journal of Molecular Medicine2001，，5： | 1 |
| 10 | High Prevalence of Celiac Disease in Italian General Population显示文摘 | Umberto Volta Stefano Bellentani Francesco Bianco Bianchi Giovanni Brandi Lucia De Franceschi Lucia Miglioli Alessandro Granito Fiorella Balli Claudio Tiribelli | 2001 | Digestive Diseases and Sciences2001，，7： | 1 |
| 11 | Adjuvant Systemic Chemotherapy After Putative Curative Resection of Colorectal Liver and Lung Metastases显示文摘 | Giovanni Brandi Enrico Derenzini Alfredo Falcone Gianluca Masi Fotios Loupakis Andrea Pietrabissa Antonio D. Pinna Giorgio Ercolani Maria A. Pantaleo Stefania Di Girolamo Gian L. Grazi Francesco de Rosa Guido Biasco | 2013 | Clinical Colorectal Cancer2013，，： | 1 |
| 12 | Osteodifferentiation of Human Preadipocytes Induced by Strontium Released from Hydrogels显示文摘 | Valeria Nardone Sergio Fabbri Francesca Marini Roberto Zonefrati Gianna Galli Annamaria Carossino Annalisa Tanini Maria Luisa Brandi Giovanni Vozzi | 2012 | International Journal of Biomaterials2012，，： | 1 |
| 13 | The Key Role of Segmented Filamentous Bacteria in the Coordinated Maturation of Gut Helper T Cell Responses显示文摘 | Valérie Gaboriau-Routhiau Sabine Rakotobe Emelyne Lécuyer Imke Mulder Anna?g Lan Chantal Bridonneau Violaine Rochet Annamaria Pisi Marianne De Paepe Giovanni Brandi Gérard Eberl Johannes Snel Denise Kelly Nadine Cerf-Bensussan | 2009 | Immunity2009，，4： | 1 |
| 14 | Combination therapy of dabrafenib plus trametinib in patients with BRAF^(V600E)-mutated biliary tract cancer显示文摘To the Editor: In the last decade, next-generation sequencing(NGS)-based molecular profiling has shed light on the molecular landscape of biliary tract cancer(BTC), revealing the presence of several potentially actionable mutations [1]. According to Clinical Trials.gov, there are at least 40 phase I to IV ongoing trials aimed at evaluating the role of targeted treatments in BTC, as monotherapy or in combination with other anticancer agents [2]. Early encouraging results have been observed with therapies targeting IDH mutations, FGFR fusions, HER family and, more recently, BRAF mutations [3]. | Alessandro Rizzo Angela Dalia Ricci Giovanni Brandi | 2021 | Hepatobiliary & Pancreatic Diseases International2021，20，5： | 1 |
| 15 | Long-term survival of two patients with recurrent pancreatic acinar cell carcinoma treated with radiofrequency ablation:A case report显示文摘BACKGROUND Pancreatic acinar cell carcinoma (PACC) is a rare type of malignant pancreatic cancer that represents approximately 1%of all pancreatic neoplasms.Due to its very low incidence,only a few retrospective studies are available.Although surgery is the first choice for treatment,most patients experience recurrence(mainly in the liver) and there are no clear recommendations for patients with advanced disease.CASE SUMMARY We report two patients with PACC treated with sturgery who experienced tumour recurrence in the liver.Patient 1 carried a germline mutation in the APC gene.Both patients were treated with gemcitabine plus oxaliplatin and gemcitabine plus capecitabine as first-and second-line therapies,respectively.After a favoturable response to chemotherapy,the patients underwent radiofrequency ablation of the remaining liver metastases.For patient 1,we documented a relapse in the liver after a disease-free period of 9 mo,and treatment with gemcitabine plus capecitabine was restarted.The patient achieved a complete response,and he remains alive without evidence of disease recurrence after six years.After radiofrequency ablation,patient 2 experienced disease-free survival for 21 mo,when peritoneal relapse was diagnosed and treated with chemotherapy.The patient achieved a stable disease state for nearly two years;nevertheless,further progressive disease was documented,and he died seven years after the first relapse.CONCLUSION PACC presents different biological behaviours than pancreatic adenocarcinoma.Multidisciplinary treatment involving local ablative therapies may be considered for PACC. | Mariacristina Di Marco Riccardo Carloni Stefania De Lorenzo Elisa Grassi Andrea Palloni Francesca Formica Stefano Brocchi Daria Maria Filippini Rita Golfieri Giovanni Brandi | 2020 | World Journal of Clinical Cases2020，8，7： | 0 |
| 16 | Pancreatic mucinous cystadenocarcinoma in a patient harbouring BRCA1 germline mutation effectively treated with olaparib: A case report显示文摘BACKGROUND Pancreatic mucinous cystadenocarcinoma(MCAC)is a rare malignancy with a poor prognosis when it presents metastases at diagnosis.Due to its very low incidence,there are no clear recommendations for the treatment of advanced disease.Olaparib(an oral PARP inhibitor)has been approved for the maintenance treatment of patients with metastatic pancreatic adenocarcinoma harbouring germline BRCA1/2 mutations.Herein,we report the first case of a germline BRCA1 mutated unresectable MCAC which was effectively treated with olaparib.CASE SUMMARY A 41-year-old woman,without personal or family history of cancer,was diagnosed with ovarian and peritoneal metastases of MCAC.She underwent 12 cycles of gemcitabine plus oxaliplatin(GEMOX)obtaining a partial response and allowing radical surgery.One year later,local recurrence was documented,and other 12 cycles of GEMOX were administered obtaining a complete response.Seven years later,another local recurrence,not amenable to surgical resection,was diagnosed.She started FOLFIRINOX(oxaliplatin,irinotecan,leucovorin and fluorouracil),obtaining a partial response after 8 cycles.Given the excellent response to platinum-based chemotherapy,BRCA testing was performed,and a BRCA1 germline mutation was detected.She was switched to maintenance olaparib due to chemotherapy-related toxicities and achieved an almost complete metabolic response,with a reduction in the diameter of the lesion,after three months of therapy.CONCLUSION The current case suggests the beneficial effect of olaparib in BRCA mutated MCAC.However,further studies are required. | Mariacristina Di Marco Riccardo Carloni Stefania De Lorenzo Cristina Mosconi Andrea Palloni Elisa Grassi Daria Maria Filippini Angela Dalia Ricci Alessandro Rizzo Alessandro Di Federico Donatella Santini Daniela Turchetti Claudio Ricci Carlo Ingaldi Laura Alberici Francesco Minni Rita Golfieri Giovanni Brandi Riccardo Casadei | 2020 | World Journal of Gastrointestinal Oncology2020，12，12： | 0 |
| 17 | The duration of the conventional chemoembolization for hepatocellular carcinoma:factors affecting the procedural time显示文摘Aim:The present study evaluated the duration of chemoembolization in patients with hepatocellular carcinoma,analyzing possible factors affecting the procedural time.Methods:In total,175 patients who underwent chemoembolization have been prospectively enrolled.The procedural length was considered the time between the insertion and the removal of the angiographic sheath.The features related to the tumor burden and angiographic procedures,which could be related to the procedural time,were recorded.Results:The chemoembolization time resulted in a mean of 58.1 min.The longer procedural time was associated with a number of nodules treated per patient≥2(P<0.001),a number of segments with nodules≥2(P<0.001),the presence of more than 1 nodule in the same segment(P<0.001),the location of the tumor in the left lobe(P=0.001),the exclusion from the Milan criteria(P<0.001),and a number of segments treated≥2(P<0.001).Only the number of nodules treated per patient resulted significantly in multivariate analysis(OR 2.927,95%CI:2.015-4.251,P<0.001).Conclusion:The factors related to longer procedural time are the number of nodules treated≥2,the number of segments with nodules≥2,the involvement of the left lobe,the tumor burden outside the Milan criteria,and the number of segments treated≥2.All these characteristics,known in the pre-procedural phase,represent useful tools for a correct planning of the angiographic room’s workflow during the pandemic era as well as in the future to reduce downtime and increase productivity. | Matteo Renzulli Mattia Gentilini Giovanni Marasco Nicolo Brandi Alessandro Granito Silvia Lo Monaco Anna Maria Ierardi Antonio De Cinque Francesco Tovoli Laura Bartalena Daniele Spinelli Fabio Piscaglia Rita Golfieri | 2022 | Hepatoma Research2022，8，1： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员